101,859 Shares in Insmed, Inc. $INSM Acquired by Tri Locum Partners LP

Key Points

• Tri Locum Partners LP has purchased 101,859 shares of Insmed, Inc. valued at approximately $7.77 million, making it the fund's 11th largest position.
• Insmed CEO William Lewis sold 129,805 shares in June, reducing his ownership by 35.69% after the sale, which amounted to over $13 million.
• Insmed's recent earnings report showed a revenue of $107.42 million for the quarter, although the company missed EPS estimates by $0.40.

Tri Locum Partners LP bought a new stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 101,859 shares of the biopharmaceutical company's stock, valued at approximately $7,771,000. Insmed accounts for about 4.0% of Tri Locum Partners LP's investment portfolio, making the stock its 11th biggest position. Tri Locum Partners LP owned approximately 0.06% of Insmed at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in INSM. MML Investors Services LLC boosted its stake in shares of Insmed by 3.4% during the fourth quarter. MML Investors Services LLC now owns 22,955 shares of the biopharmaceutical company's stock valued at $1,585,000 after purchasing an additional 754 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Insmed by 62.5% during the fourth quarter. Hsbc Holdings PLC now owns 21,108 shares of the biopharmaceutical company's stock valued at $1,449,000 after purchasing an additional 8,122 shares during the period. Public Employees Retirement Association of Colorado boosted its stake in shares of Insmed by 40.5% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 19,574 shares of the biopharmaceutical company's stock valued at $1,351,000 after purchasing an additional 5,639 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Insmed by 8.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 313,181 shares of the biopharmaceutical company's stock valued at $21,622,000 after purchasing an additional 25,108 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Insmed by 19.9% during the fourth quarter. Northern Trust Corp now owns 1,750,642 shares of the biopharmaceutical company's stock valued at $120,864,000 after purchasing an additional 290,678 shares during the period.

Insider Activity

In other news, CEO William Lewis sold 129,805 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at $23,483,630.36. This represents a 35.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the transaction, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 515,927 shares of company stock valued at $51,447,211. 3.00% of the stock is owned by company insiders.

Insmed Stock Up 6.2%

Insmed stock traded up $8.46 during trading hours on Tuesday, reaching $144.56. The stock had a trading volume of 2,726,181 shares, compared to its average volume of 2,798,488. The company has a market cap of $30.56 billion, a price-to-earnings ratio of -25.12 and a beta of 0.96. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business's 50 day moving average price is $111.35 and its 200-day moving average price is $88.01. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $146.18.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter last year, the company earned ($1.94) EPS. The business's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on INSM. Truist Financial upped their price objective on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Jefferies Financial Group upped their price objective on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. UBS Group upped their price objective on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. William Blair began coverage on shares of Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating for the company. Finally, Royal Bank Of Canada upped their price objective on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and a consensus target price of $132.57.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.